Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Lower Radiotherapy Dose Shows Promise for Treating HPV-Related Oropharyngeal Cancer

March 3, 2021
By Hannah Slater
Article

Given the current study findings, investigators suggested intratherapy personalization of chemoradiotherapy may possibly facilitate marked de-escalation of radiotherapy in patients with HPV-related oropharyngeal cancers.

De-escalation of radiotherapy to 30 Gy on the basis of intratreatment hypoxia imaging among patients with head and neck cancers related to human papillomavirus (HPV) infection is feasible, safe, and associated with minimal toxicity, according to a pilot study published in the Journal of the National Cancer Institute.1

Patients with HPV-related oropharyngeal cancers typically have good outcomes but experience clinically significant toxicities when treated with standard chemoradiotherapy at a dose of 70 Gy. Given the current study findings, investigators suggested intratherapy personalization of chemoradiotherapy may possibly facilitate marked de-escalation of radiotherapy.

“This is an absolute game changer for treating HPV-positive cancer,” lead author Nancy Lee, MD, a radiation oncologist at Memorial Sloan Kettering Cancer Center, said in a press release.2 “The difference in toxicity is dramatic compared with standard radiation therapy.”

In this study, investigators used pre- and intratreatment dynamic fluorine-18–labeled fluoromisonidazole PET to evaluate tumor hypoxia in 19 patients. Patients without hypoxia at baseline or intratreatment received 30 Gy of chemoradiotherapy, and those with persistent hypoxia received 70 Gy. Of note, neck dissection was conducted at 4 months among de-escalated patients to determine pathologic response.

“Reducing the radiation dose to 30 Gy for HPV-positive head and neck cancer seemed feasible because HPV-positive anal cancer has been treated effectively with that dosage,” added Lee.

Overall, 15 of 19 patients had no hypoxia on baseline PET or resolution on intratreatment PET and were deescalated to 30 Gy. Of these patients, 11 had a pathologic complete response.

Two-year locoregional control was 94.4% (95% CI, 84.4%-100%) and overall survival was 94.7% (95% CI, 85.2%-100%). No acute grade 3 radiation-related toxicities were observed.

“It’s hard to describe the huge difference this makes,” first author Nadeem Riaz, MD, MSc, radiation oncologist at Memorial Sloan Kettering Cancer Center, said in the release. “With the 7-week treatment, patients typically lose 20 to 30 pounds and may have to go on work disability for several months. When receiving the smaller dose over just 3 weeks, they have almost no radiation side effects. It’s like you’re not even using the same treatment.”

On serial imaging, microenvironmental features were found to have correlated better with pathologic response than tumor burden metrics or circulating plasma cell-free DNA. Further, a whole genome sequencing–based DNA repair defect was associated with response (P =.02) and was reproduced in an independent cohort (P =.03).

Notably, the success of the current study has led to the development of a Precision Radiotherapy Program at Memorial Sloan Kettering Cancer Center. This new program is intended to develop similar studies aimed at making radiation treatments more personalized for each patient’s cancer, regardless of its location.

“Radiation therapy has proven to be one of the most effective cancer treatments,” Simon N. Powell, MD, PhD, FRCP, radiation oncologist and chair of the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center, said in the release. “The ultimate goal of our initiative is to make radiation therapy a targeted treatment based on the biology of the tumor and the characteristics of the patients.”

References:

1. Riaz N, Sherman E, Pei X, et al. Precision radiotherapy: reduction in radiation for oropharyngeal cancer in the 30 ROC trial. JNCI: Jour Nat Cancer Inst. Published online January 12, 2021. doi: 10.1093/jnci/djaa184

2. Low-dose radiation a possible “game changer” for treating HPV-positive throat cancer. News release. Memorial Sloan Kettering Cancer Center. Published January 25, 2021. Accessed February 19, 2021. https://www.mskcc.org/news/low-dose-radiation-possible-game-changer-treating-hpv-positive-head-and-neck

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
Related Content

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.


David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.


From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm

Russ Conroy
May 23rd 2025
Article

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.


Efti plus pembrolizumab demonstrated no new safety signals in the TACTI-003 trial.

Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC

Russ Conroy
May 8th 2025
Article

Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.


Event-free survival events were observed in 37.5% of patients taking pembrolizumab vs 45.3% without among patients with resectable locally advanced HNSCC.

Perioperative Pembrolizumab Enhances Survival in Locally Advanced HNSCC

Ashley Chan
April 30th 2025
Article

Event-free survival events were observed in 37.5% of patients with resectable locally advanced HNSCC who took pembrolizumab vs 45.3% in those who did not.


Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.

FDA Approves Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma

Roman Fabbricatore
April 24th 2025
Article

Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.

Related Content

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.


David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.


From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm

Russ Conroy
May 23rd 2025
Article

From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.


Efti plus pembrolizumab demonstrated no new safety signals in the TACTI-003 trial.

Frontline Efti Combo Yields Meaningful Survival in PD-L1–Low HNSCC

Russ Conroy
May 8th 2025
Article

Survival data with eftilagimod alfa plus pembrolizumab compare favorably with historical results seen with standard-of-care therapies in this population.


Event-free survival events were observed in 37.5% of patients taking pembrolizumab vs 45.3% without among patients with resectable locally advanced HNSCC.

Perioperative Pembrolizumab Enhances Survival in Locally Advanced HNSCC

Ashley Chan
April 30th 2025
Article

Event-free survival events were observed in 37.5% of patients with resectable locally advanced HNSCC who took pembrolizumab vs 45.3% in those who did not.


Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.

FDA Approves Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma

Roman Fabbricatore
April 24th 2025
Article

Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.